Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 6/2018

01-06-2018 | Original Article

The association of short-term memory and cognitive impairment with ghrelin, leptin, and cortisol levels in non-diabetic and diabetic elderly individuals

Authors: Yu Ming Sang, Li Jun Wang, Hong Xian Mao, Xue Yong Lou, Yi Jun Zhu

Published in: Acta Diabetologica | Issue 6/2018

Login to get access

Abstract

Aims

This study assessed short-term memory and biochemical indicators with the levels of ghrelin, leptin, and cortisol between cognitive impairment and normal older adults with or without diabetes.

Methods

We enrolled 286 older adults (aged 65–85 years) with or without diabetes from the local community. Short-term memory was assessed using pictures of common objects; cognitive functioning was assessed using the Mini–Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The physiological indexes assessed were plasma levels of fasting ghrelin and leptin, ghrelin level at 2_h after breakfast, 24-h urinary cortisol value, body mass index, and plasma cortisol levels at 8:00 a.m., 4:00 p.m., and 12:00 p.m.

Results

In both non-diabetic and diabetic subjects, short-term memory was significantly lower in the impaired cognition group (5.99 ± 2.90 in non-diabetic subjects and 4.71 ± 2.14 in diabetic subjects) than in the normal cognition group (8.14 ± 2.23 in non-diabetic subjects and 7.82 ± 3.37 in diabetic subjects). Baseline ghrelin level was significantly lower in the impaired cognition group (9.07 ± 1.13 ng/mL in non-diabetic subjects and 7.76 ± 1.34 ng/mL in diabetic subjects) than in the normal cognition group (10.94 ± 1.53 ng/mL in non-diabetic subjects and 9.93 ± 1.76 ng/mL in diabetic subjects); plasma cortisol levels at 8:00 a.m., 4:00 p.m., and 12:00 p.m. were significantly higher in the impaired cognition group than in the normal cognition group, while no significant difference was observed in plasma levels of fasting leptin between different groups.

Conclusions

Fasting plasma ghrelin and cortisol levels may be markers of cognitive decline and memory loss. It is possible that adjusting their levels may have a therapeutic effect, and this should be investigated in future studies.
Literature
1.
Ning G, Bloomgarden Z (2013) Diabetes in China: prevalence, diagnosis, and control. J Diabetes 5(4):372CrossRefPubMed
2.
Bianchi L, Volpato S (2016) Muscle dysfunction in type 2 diabetes: a major threat to patient’s mobility and independence. Acta Diabetol 53(6):879–889CrossRefPubMed
3.
Sattar L, Renneboog B, Decaux G (2017) Hyperglycemia induces attention and gait deficits in diabetic mellitus patients. Acta Diabetol 54(10):953–959CrossRefPubMed
4.
Simó R, Ciudin A, Simó-Servat O, Hernández C (2017) Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—The diabetologist’s perspective. Acta Diabetol 54(5):417–424CrossRefPubMed
5.
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74CrossRefPubMed
6.
Martins I, Gomes S, Costa RO et al (2013) Leptin and ghrelin prevent hippocampal dysfunction induced by Aβ oligomers. Neuroscience 41:41–51CrossRef
7.
Diano S, Farr SA, Benoit SC et al (2006) Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 9:381–388CrossRefPubMed
8.
Oomura Y, Hori N, Shiraishi T et al (2006) Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 27:2738–2749CrossRefPubMed
9.
McNay EC (2007) Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function. Curr Opin Pharmacol 7:628–632CrossRefPubMed
10.
11.
12.
Castañeda TR, Tong J, Datta R et al (2010) Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 31:44–60CrossRefPubMed
13.
Beheshti S, Shahrokhi S (2015) Blocking the ghrelin receptor type 1a in the rat brain impairs memory encoding. Neuropeptides 52:97–102CrossRefPubMed
14.
Zhu Q, Xiao K, Yu M et al (2013) Ghrelin but not nesfatin-1 affects certain forms of learning and memory in both rats and mice. Brain Res 1541:42–51CrossRefPubMed
15.
Babri S, Amani M, Mohaddes G et al (2013) Effects of intrahippocampal injection of ghrelin on spatial memory in PTZ-induced seizures in male rats. Neuropeptides 47:355–360CrossRefPubMed
16.
Goshadrou F, Kermani M, Ronaghi A et al (2013) The effect of ghrelin on MK-801 induced memory impairment in rats. Peptides 44:60–65CrossRefPubMed
17.
Wang J, Ni J, Dong J et al (2013) Ghrelin increases hippocampal recombination activating gene 1 expression and spatial memory performance in mice. NeuroReport 24:712–717CrossRefPubMed
18.
Gomes S, Martins I, Fonseca ACRG et al (2014) Protective effect of leptin and ghrelin against toxicity induced by amyloid-β oligomers in a hypothalamic cell line. J Neuroendocrinol 26:176–185CrossRefPubMed
19.
Bayliss JA, Andrews ZB (2013) Ghrelin is neuroprotective in Parkinson’s disease: molecular mechanisms of metabolic neuroprotection. Ther Adv Endocrinol Metab 4:25–36CrossRefPubMedPubMedCentral
20.
Dhurandhar E, Allison D, Groen T et al (2013) Hunger in the absence of caloric restriction improves cognition and attenuates Alzheimer’s disease pathology in a mouse model. PLoS ONE 8:2–9CrossRef
21.
Kunath N, van Groen T, Allison DB et al (2015) Ghrelin agonist does not foster insulin resistance but improves cognition in an Alzheimer’s disease mouse model. Sci Rep 5:11452CrossRefPubMedPubMedCentral
22.
Kunath N, Dresler M (2014) Ghrelin and memory. In: Portelli J, Smolders I (eds) Central functions of the ghrelin receptor. Springer, New York, pp 167–175
23.
Steiger A, Dresler M, Schüssler P et al (2011) Ghrelin in mental health, sleep, memory. Mol Cell Endocrinol 340:88–96CrossRefPubMed
24.
Spitznagel MB, Benitez A, Updegraff J et al (2010) Serum ghrelin is inversely associated with cognitive function in a sample of non-demented elderly. Psychiatr Clin Neurosci 64:608–611CrossRef
25.
Klok MD, Jakobsdottir S, Drent ML (2007) The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8:21–34CrossRefPubMed
26.
27.
28.
Fewlass DC, Noboa K, Pi-Sunyer FX et al (2004) Obesity-related leptin regulates Alzheimers Aβ. FASEB J 18:1870–1878CrossRefPubMed
29.
30.
Gecici O, Kuloglu M, Atmaca M et al (2005) High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin Neurosci 59:736–738CrossRefPubMed
31.
Antonijevic IA, Murck H, Frieboes RM et al (1998) Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res 32:403–410CrossRefPubMed
32.
33.
Guey-Mei J, Tsung-Tsair Y, Chun-Lan C (2006) Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 90:21–27CrossRef
34.
Deuschle M, Blum WF, Englaro P et al (1996) Plasma leptin in depressed patients and healthy controls. Horm Metab Res 28(714):7 [PubMed: 9013749]
35.
36.
Milaneschi Y, Simonsick EM, Vogelzangs N et al (2012) Leptin, abdominal obesity, and onset of depression in older men and women. J Clin Psychiatry 73:1205–1211CrossRefPubMedPubMedCentral
37.
Milaneschi Y, Sutin AR, Terracciano A et al (2014) The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology 42:1–10CrossRefPubMedPubMedCentral
38.
Spencer SJ, Emmerzaal TL, Kozicz T et al (2015) Ghrelin’s role in the hypothalamic-pituitary-adrenal axis stress response: implications for mood disorders. Biol Psychiatry 78:19–27CrossRefPubMed
39.
Lara VP, Caramelli P, Teixeira AL et al (2013) High cortisol levels are associated with cognitive impairment no-dementia (CIND) and dementia. Clin Chim Acta 423:18–22CrossRefPubMed
40.
Karlamangla AS, Singer BH, Chodosh J et al (2005) Urinary cortisol excretion as a predictor of incident cognitive impairment. Neurobiol Aging 26(Suppl1):S80–S84CrossRef
41.
Lupien SJ, Fiocco A, Wan N et al (2005) Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology 30:225–242CrossRefPubMed
42.
Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed
43.
Kathol RG, Jaeckel RS, Lopez JF et al (1989) Pathophysiology of HPA axis abnormalities in patients with major depression: an update. Am J Psychiatry 146:311–317CrossRefPubMed
44.
Katzman R, Zhang MY, Ouang YQ et al (1988) A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol 41(10):971–978CrossRefPubMed
45.
Wang ZY, Zhang MT (1989) Application of simple intelligent state checking (MMSE) in Chinese version. Shanghai Psychiatric Med 7(3):108–111 (In Chinese)
46.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V et al (2005) The Montreal Cognitive Assessment, MoCA: brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699CrossRefPubMed
47.
Wang MQ, Ren MS (2012) Value of Montreal cognitive assessment in identifying ischemic stroke patients. Chin J Clin Neurosci 20(2):199–204
48.
49.
Aziz MA, Sharaby MA (1993) Collinearity as a problem in predicting body weight from body dimensions of Najdi sheep in Saudi Arabia. Small Rumin Res 12:117–124CrossRef
50.
Yakubu A, Fakuade OF, Faith EA, Musa-Azara IS, Ogunwole OA (2013) Determination of prediction equations to estimate body condition score from body size and testicular traits of yankasa rams. J Indonesian Trop Anim 38(2):79–85
51.
Stoyanova II (2014) Ghrelin: a link between aging, metabolism and neurodegenerative disorders. Neurobiol Dis 72:72–83CrossRefPubMed
52.
Kunath N, Muller NCJ, Tonon M et al (2016) Ghrelin modulates encoding-related brain function without enhancing memory formation in humans. NeuroImage 142:465–473CrossRefPubMed
53.
Wittekind DA, Kluge M (2015) Ghrelin in psychiatric disorders-A review. Psychoneuroendocrinology 52:176–194CrossRefPubMed
54.
Vasiliadis HM, Forget H, Préville M (2013) The association between self-reported daily hassles and cortisol levels in depression and anxiety in community living older adults. Int J Geriatr Psychiatry 28:991–997CrossRefPubMed
55.
Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (second of two parts). N Engl J Med 319:413–420CrossRefPubMed
56.
Martin EI, Ressler KJ, Binder E et al (2009) The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 32:549–575CrossRefPubMedPubMedCentral
57.
Vreeburg SA, Hoogendijk WJ, van Pelt J et al (2009) Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66:617–626CrossRefPubMed
58.
Van Santen A, Vreeburg SA, Van der Does AJ et al (2011) Psychological traits and the cortisol awakening response: results from the Netherlands Study of Depression and Anxiety. Psychoneuroendocrinology 36:240–248CrossRefPubMed
59.
Balardin JB, Vedana G, Luz C et al (2011) Subjective mild depressive symptoms are associated with abnormal diurnal cycle of salivary cortisol in older adults. J Geriatr Psychiatry Neurol 24(1):19–22CrossRefPubMed
60.
Pruessner JC, Hellhammer DH, Kirschbaum C (1999) Burnout, perceived stress, and cortisol responses to awakening. Psychosom Med 61:197–204CrossRefPubMed
Metadata
Title
The association of short-term memory and cognitive impairment with ghrelin, leptin, and cortisol levels in non-diabetic and diabetic elderly individuals
Authors
Yu Ming Sang
Li Jun Wang
Hong Xian Mao
Xue Yong Lou
Yi Jun Zhu
Publication date
01-06-2018
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 6/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1111-5

Other articles of this Issue 6/2018

Acta Diabetologica 6/2018 Go to the issue

Review Article

The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia

Original Article

Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study

Original Article

The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo

Original Article

Sex differences in the association of psychological status with measures of physical activity and sedentary behaviour in adults with type 2 diabetes

Original Article

History of spontaneous miscarriage and the risk of diabetes mellitus among middle-aged and older Chinese women

Original Article

Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits